articles with this tag
ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await
Nov 7, 2019
One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.
IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy
Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?
Jan 31, 2019
Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.